Targeted Covalent Inhibitors for the Treatment of Malaria?

Malaria is a vector-borne disease caused by protozoan parasites of the genus . According to the World Health Organization, it is one of the most serious infectious diseases threatening more than 3 billion people worldwide. In recent years, targeted covalent inhibitors (TCIs) have gained a lot of att...

Full description

Saved in:
Bibliographic Details
Published in:ACS infectious diseases Vol. 6; no. 11; p. 2815
Main Authors: Kulkarni, Shashank, Urbahns, Klaus, Spangenberg, Thomas
Format: Journal Article
Language:English
Published: United States 13.11.2020
ISSN:2373-8227, 2373-8227
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Malaria is a vector-borne disease caused by protozoan parasites of the genus . According to the World Health Organization, it is one of the most serious infectious diseases threatening more than 3 billion people worldwide. In recent years, targeted covalent inhibitors (TCIs) have gained a lot of attention and several TCI-based drugs have been approved across different therapeutic areas. For malaria, surprisingly, this approach has not been explored in depth even though lot of advancements have been made in understanding the biology of the parasite. Herein, we present our views on exploring TCIs as a new class of antimalarial agents.
AbstractList Malaria is a vector-borne disease caused by protozoan parasites of the genus . According to the World Health Organization, it is one of the most serious infectious diseases threatening more than 3 billion people worldwide. In recent years, targeted covalent inhibitors (TCIs) have gained a lot of attention and several TCI-based drugs have been approved across different therapeutic areas. For malaria, surprisingly, this approach has not been explored in depth even though lot of advancements have been made in understanding the biology of the parasite. Herein, we present our views on exploring TCIs as a new class of antimalarial agents.
Malaria is a vector-borne disease caused by protozoan parasites of the genus Plasmodium. According to the World Health Organization, it is one of the most serious infectious diseases threatening more than 3 billion people worldwide. In recent years, targeted covalent inhibitors (TCIs) have gained a lot of attention and several TCI-based drugs have been approved across different therapeutic areas. For malaria, surprisingly, this approach has not been explored in depth even though lot of advancements have been made in understanding the biology of the parasite. Herein, we present our views on exploring TCIs as a new class of antimalarial agents.Malaria is a vector-borne disease caused by protozoan parasites of the genus Plasmodium. According to the World Health Organization, it is one of the most serious infectious diseases threatening more than 3 billion people worldwide. In recent years, targeted covalent inhibitors (TCIs) have gained a lot of attention and several TCI-based drugs have been approved across different therapeutic areas. For malaria, surprisingly, this approach has not been explored in depth even though lot of advancements have been made in understanding the biology of the parasite. Herein, we present our views on exploring TCIs as a new class of antimalarial agents.
Author Urbahns, Klaus
Spangenberg, Thomas
Kulkarni, Shashank
Author_xml – sequence: 1
  givenname: Shashank
  surname: Kulkarni
  fullname: Kulkarni, Shashank
  organization: Global Health Institute of Merck, Ares Trading S.A., a subsidiary of Merck KGaA (Darmstadt, Germany), 1261 Eysins, Switzerland
– sequence: 2
  givenname: Klaus
  surname: Urbahns
  fullname: Urbahns, Klaus
  organization: Merck Healthcare KGaA, 64293 Darmstadt, Germany
– sequence: 3
  givenname: Thomas
  orcidid: 0000-0002-5654-8919
  surname: Spangenberg
  fullname: Spangenberg, Thomas
  organization: Global Health Institute of Merck, Ares Trading S.A., a subsidiary of Merck KGaA (Darmstadt, Germany), 1261 Eysins, Switzerland
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33054158$$D View this record in MEDLINE/PubMed
BookMark eNpNj01LAzEYhINUbK39BYLs0cvWfGyyiReR4keh4qWel2zyxkZ2NzVJhf57LVbwNAPzMMyco9EQBkDokuA5wZTcaJP84MBYn-bYYCxkdYImlNWslJTWo39-jGYpfWCMCZO8qvgZGjOGeUW4nKDbtY7vkMEWi_ClOxhysRw2vvU5xFS4EIu8gWIdQef-EAZXvOhOR6_vLtCp012C2VGn6O3xYb14LlevT8vF_arUTOFcWl07QQAYttgyqDUh1CjBLROqJcq4Wlonf5a1ygrFHHNO6srUXACHVkk6Rde_vdsYPneQctP7ZKDr9ABhlxpacSIFZfiAXh3RXduDbbbR9zrum7-_9BsnUFvP
CitedBy_id crossref_primary_10_3390_ph16071028
crossref_primary_10_1016_j_pt_2022_07_001
ContentType Journal Article
DBID NPM
7X8
DOI 10.1021/acsinfecdis.0c00684
DatabaseName PubMed
MEDLINE - Academic
DatabaseTitle PubMed
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 2373-8227
ExternalDocumentID 33054158
Genre Journal Article
GroupedDBID 53G
ABJNI
ABMVS
ABQRX
ABUCX
ACGFS
ACS
ADHLV
AEESW
AFEFF
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
BAANH
CUPRZ
EBS
GGK
NPM
UI2
VF5
VG9
W1F
7X8
ABBLG
ABLBI
ID FETCH-LOGICAL-a390t-da7f61ee30d0d3e7a112c965d369b19cf78df8854b9d693f3ff8a4c756e5eb982
IEDL.DBID 7X8
ISICitedReferencesCount 4
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000592747600003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2373-8227
IngestDate Fri Jul 11 10:25:18 EDT 2025
Wed Feb 19 02:30:02 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 11
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a390t-da7f61ee30d0d3e7a112c965d369b19cf78df8854b9d693f3ff8a4c756e5eb982
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-5654-8919
OpenAccessLink https://pubs.acs.org/doi/pdf/10.1021/acsinfecdis.0c00684
PMID 33054158
PQID 2451862308
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2451862308
pubmed_primary_33054158
PublicationCentury 2000
PublicationDate 2020-11-13
20201113
PublicationDateYYYYMMDD 2020-11-13
PublicationDate_xml – month: 11
  year: 2020
  text: 2020-11-13
  day: 13
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle ACS infectious diseases
PublicationTitleAlternate ACS Infect Dis
PublicationYear 2020
SSID ssj0001385445
Score 2.1810982
SecondaryResourceType review_article
Snippet Malaria is a vector-borne disease caused by protozoan parasites of the genus . According to the World Health Organization, it is one of the most serious...
Malaria is a vector-borne disease caused by protozoan parasites of the genus Plasmodium. According to the World Health Organization, it is one of the most...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 2815
Title Targeted Covalent Inhibitors for the Treatment of Malaria?
URI https://www.ncbi.nlm.nih.gov/pubmed/33054158
https://www.proquest.com/docview/2451862308
Volume 6
WOSCitedRecordID wos000592747600003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvAazWY32V0vRYpFDy09VOgt7BNzSaqp_n5n04SeBMFDcguEyWTmm5lv50PoTkJQtGHDJScaChRGkkgxk0YK_ElpSW1iVCM2wScTMZ_Ladtwq1taZRcTm0BtKxN65A8JSwmgbxqLweIjCqpRYbraSmhsoh4FKBMoXXwu1j0WKsKumUZfjtMIciHvFg8l5EGZuiE82aK-j004K8F-h5lNuhnt__dFD9BeCzTx08ozDtGGK4_QzrgdpR-jx1nDAXcWDyvwNsg9-LV8L3QR5HcwQFkM0BDPOh46rjweKyiDCzU4QW-j59nwJWqFFMDkMl5GVnGfEedobGNLHVcAsozMUkszqYk0ngvrBdhKS5tJ6qn3Ar4YTzOXOi1Fcoq2yqp05wjLOHPSsFh76RjTRqexhUsBDtGMENlHt51VcnDUMH1Qpau-6nxtlz46W5k2X6w2auQUog4gCXHxh6cv0W4Sat5AxaNXqOfhN3XXaNt8L4v686bxALhPpuMfSR66Ug
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeted+Covalent+Inhibitors+for+the+Treatment+of+Malaria%3F&rft.jtitle=ACS+infectious+diseases&rft.au=Kulkarni%2C+Shashank&rft.au=Urbahns%2C+Klaus&rft.au=Spangenberg%2C+Thomas&rft.date=2020-11-13&rft.issn=2373-8227&rft.eissn=2373-8227&rft.volume=6&rft.issue=11&rft.spage=2815&rft_id=info:doi/10.1021%2Facsinfecdis.0c00684&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2373-8227&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2373-8227&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2373-8227&client=summon